Market research
JAGSNPHARM.NSE Jagsonpal Pharmaceuticals Limited
NSE INR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15B
- P/E ratio
- 34.71
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- -0.28
Community
Investor discussion
1 comment
Sign in to join the JAGSNPHARM.NSE discussion.
5 years, 5 months ago
Jagsonpal Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 82.0% above its 200 day moving average.
From a valuation standpoint, the stock is 74.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.2.
Jagsonpal Pharmaceuticals Limited's total revenue rose by 35.9% to $571M since the same quarter in the previous year.
Its net income has increased by 137.8% to $54M since the same quarter in the previous year.
Finally, its free cash flow grew by 297.1% to $170M since the same quarter in the previous year.
Based on the above factors, Jagsonpal Pharmaceuticals Limited gets an overall score of 5/5.